Literature DB >> 31206727

Comparison of published risk models for prediction of outcome in patients with extrameningeal solitary fibrous tumour.

Elizabeth G Demicco1,2, Anthony M Griffin3,4, Rebecca A Gladdy5,6,7, Brendan C Dickson1,2, Peter C Ferguson3,4, Carol J Swallow5,6,7, Jay S Wunder3,4, Wei-Lien Wang8,9.   

Abstract

AIMS: Solitary fibrous tumours (SFTs) are fibroblastic mesenchymal tumours with a 10-30% metastatic rate. Several risk models have been proposed for extrameningeal SFT, but they have not been evaluated in direct comparison with each other. The aim of this study is to compare the utility of published risk models in a multi-institutional SFT cohort. METHODS AND
RESULTS: Clinicopathological data were evaluated for a cohort of extrameningeal SFTs, and used to stratify tumours by the use of five proposed risk models designed for soft tissue and/or pleural SFT [modified Demicco, Pasquali, Salas overall survival (OS), Salas metastasis, and Salas local recurrence (LR)]. Kaplan-Meier and Cox proportional hazards models were used to assess OS, time to first metastasis, time to first LR, and recurrence-free survival (RFS). The study included 303 patients (109 from a referral cancer treatment centre; previously described in the original Demicco model) and an independent cohort from two large hospitals (n = 194). The median patient age was 54 years, and the median clinical follow-up (available for 220 patients) was 37 months. The independent cohort had a 13% risk of metastasis at 5 years and a 16% risk of metastasis at 10 years. In this cohort, the modified Demicco, Salas OS, and Salas metastasis models predicted metastasis and RFS, whereas the Pasquali model had the best correlation with OS.
CONCLUSIONS: Multivariate risk models that include mitotic rate and patient age can more accurately predict aggressive behaviour in SFTs, with the modified Demicco and Salas OS risk models showing the best correlation with metastasis and RFS.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  metastasis; prognosis; risk assessment; solitary fibrous tumour

Mesh:

Year:  2019        PMID: 31206727     DOI: 10.1111/his.13940

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  Orbit Solitary Fibrous Tumor: A Proposed Risk Prediction Model Based on a Case Series and Comprehensive Literature Review.

Authors:  Lester D R Thompson; Sofia S Liou; Kenneth A Feldman
Journal:  Head Neck Pathol       Date:  2020-06-11

2.  Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.

Authors:  Michel Kalamarides; Gaëlle Pierron; Caroline Apra; Delphine Guillemot; Eléonore Frouin; Corinne Bouvier; Karima Mokhtari
Journal:  J Neurooncol       Date:  2021-08-20       Impact factor: 4.130

3.  A Case Report of Rare Sacral Solitary Fibrous Tumor.

Authors:  Lukas Kvaščevičius; Eligijus Poškus; Donatas Petroška; Dimitrij Šeinin; Robertas Kvaščevičius
Journal:  Cureus       Date:  2022-07-31

4.  RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.

Authors:  Wei-Lien Wang; Nalan Gokgoz; Bana Samman; Irene L Andrulis; Jay S Wunder; Elizabeth G Demicco
Journal:  Mod Pathol       Date:  2020-10-02       Impact factor: 7.842

Review 5.  Mesenchymal tumours of the gastrointestinal tract.

Authors:  Marta Sbaraglia; Gianluca Businello; Elena Bellan; Matteo Fassan; Angelo Paolo Dei Tos
Journal:  Pathologica       Date:  2021-06

6.  Intracranial malignant solitary fibrous tumor metastasized to the chest wall: A case report and review of literature.

Authors:  Daisuke Usuda; Shinya Yamada; Toshihide Izumida; Ryusho Sangen; Toshihiro Higashikawa; Ken Nakagawa; Masaharu Iguchi; Yuji Kasamaki
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.